

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CLINUVEL PHARMACEUTICALS LTD
ABN	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stan McLiesh
Date of last notice	05 August 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest (Ordinary Shares) Direct Interest (Unlisted Conditional Performance Rights)
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares held on behalf of Director by the Clinuvel Conditional Performance Rights Scheme Trust (Registered Holder : ACN 108 768 896 PTY LTD)
Date of change	06 December to 12 December 2016
No. of securities held prior to change	211,000 Ordinary Shares (includes 135,000 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust) 65,000 Unlisted Conditional Performance Rights
Class	Ordinary Shares
Number acquired	N/A
Number disposed	47,328 Ordinary Shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$364,431

No. of securities held after change	163,672 Ordinary Shares (includes 135,000 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust) 65,000 Unlisted Conditional Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market sale of ordinary shares

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a